DNAJB6b: a complete amyloid inhibitor
- 1Lund University
Abstract
In Alzheimer's disease (AD), the aggregation of amyloid {beta} (A{beta}) peptides has been linked to disease pathology. Once aggregates have formed, existing fibrils catalyze the formation of new fibrils in a runaway process associated with neuro degeneration. One component of the cellular defense system against amyloid formation is the molecular chaperone DNAJB6b (JB6). JB6 is known to suppress both primary nucleation and fibril-catalyzed secondary nucleation. However, the extent of JB6 binding to A{beta} fibrils and whether this interaction leads to inhibition of fibril elongation also, have not been established. Here, we combine well-characterized aggregation kinetics of A{beta}42 and the knowledge of JB6 self-assembly equilibrium and kinetics, with high-sensitivity HPLC measurements of free JB6 at nanomolar concentrations to determine the affinity of JB6 for A{beta}42 fibrils. We show that JB6 binds to A{beta}42 fibrils with high affinity and that this binding can quantitatively explain the observed elongation inhibition. Diffusion-based techniques reveal that JB6 binds to amyloid intermediates, resulting in potent suppression of amyloid nucleation until the pool of free JB6 is depleted, after which rapid bulk aggregation ensues. Our results provide a mechanistic link between chaperone-fibril binding and amyloid suppression, offering a quantitative framework for understanding how molecular chaperones regulate amyloid formation.
Related
- Post-transplant BRAF/MEK inhibitor maintenance sustains complete remission in BRAF V600E-mutant histiocytic sarcoma.
- Drug-Drug Interaction Signals Between Anti-Amyloid-β Antibodies and Antithrombotic Drugs for Amyloid-Related Imaging Abnormalities and Intracranial Hemorrhage: A FAERS Disproportionality Analysis
- Dementia with Lewy bodies and amyloid pathology: Eligible for anti‐amyloid treatment or not?
- Toward selective amyloid clearance through rational nanomedicine design
- Beyond the amyloid−β framework: reconsidering the complementary role of tau-related mechanisms in sleep-cognition research
BibTeX
@misc{carlsson2026dnajb6b,
title = {{DNAJB6b: a complete amyloid inhibitor}},
author = {A. Carlsson and U. Olsson and S. Linse},
howpublished = {bioRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.03.749188},
url = {https://www.biorxiv.org/content/10.64898/2026.09.03.749188v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - DNAJB6b: a complete amyloid inhibitor
AU - A. Carlsson
AU - U. Olsson
AU - S. Linse
PY - 2026
DA - 2026/09/03
PB - bioRxiv
DO - 10.64898/2026.09.03.749188
UR - https://www.biorxiv.org/content/10.64898/2026.09.03.749188v1
AB - In Alzheimer's disease (AD), the aggregation of amyloid {beta} (A{beta}) peptides has been linked to disease pathology. Once aggregates have formed, existing fibrils catalyze the formation of new fibrils in a runaway process associated with neuro degeneration. One component of the cellular defense system against amyloid formation is the molecular chaperone DNAJB6b (JB6). JB6 is known to suppress both primary nucleation and fibril-catalyzed secondary nucleation. However, the extent of JB6 binding to A{beta} fibrils and whether this interaction leads to inhibition of fibril elongation also, have not been established. Here, we combine well-characterized aggregation kinetics of A{beta}42 and the knowledge of JB6 self-assembly equilibrium and kinetics, with high-sensitivity HPLC measurements of free JB6 at nanomolar concentrations to determine the affinity of JB6 for A{beta}42 fibrils. We show that JB6 binds to A{beta}42 fibrils with high affinity and that this binding can quantitatively explain the observed elongation inhibition. Diffusion-based techniques reveal that JB6 binds to amyloid intermediates, resulting in potent suppression of amyloid nucleation until the pool of free JB6 is depleted, after which rapid bulk aggregation ensues. Our results provide a mechanistic link between chaperone-fibril binding and amyloid suppression, offering a quantitative framework for understanding how molecular chaperones regulate amyloid formation.
ER -